One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

Quick Read

Lilly’s incretin franchise hit ~$15B in a single quarter while LLY shares surged 56% over the past year, leaving PFE trading at just 9x forward earnings with a 6.22% yield.
Retatrutide’s BLA filing in Q1 2027 across obesity, sleep apnea, and osteoarthritis pain is Lilly’s biggest swing catalyst, backed by 19 upward analyst EPS revisions in 30 days.
Pfizer suits income investors seeking yield during a turnaround, but Lilly is the stronger 2027 growth pick if you can stomach the premium valuation.
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn’t make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.

Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE) just gave investors two very different pharma stories. Lilly’s latest quarter showcased runaway incretin demand and a raised outlook. Pfizer’s showed a diversified book slowly stabilizing after COVID, with a fresh obesity bet stapled on. Heading into 2027, the question is whether uncapped growth or defensive transformation deserves your capital.

Mounjaro Runs the Table, Pfizer Steadies the Base

Lilly’s Q2 2026 earnings report was category-defining. Revenue hit $22.97B, up 47.7% year over year, driven by Mounjaro at $9.94B (+91%) and Zepbound at $4.93B (+46%). International Mounjaro sales jumped 172% following China NRDL listing, a real signal that GLP-1 demand is global. CEO David Ricks called Lilly’s future “never been brighter” after 150 years, and management raised FY2026 revenue guidance to $85.0B to $87.0B.

Pfizer’s Q1 2026 was quieter but more encouraging than skeptics expected. Revenue reached $14.45B, up 5.4%, with adjusted EPS of $0.75. Growth came from newer assets: Padcev at $591M (+39%), Nurtec at $353M (+42%), and oncology biosimilars at $409M (+55%). COVID drag continued, with Comirnaty down 59% and Paxlovid down 62%. Albert Bourla told investors Pfizer will “successfully navigate this defining period”, leaning on oncology and a late obesity push.

Free Report, Just Released

Why Didn’t LLY Make The Top 10 List?

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

And LLY didn’t make the cut!

The report is free, and you can see why we think each stock is a top investment today.

Enter Your Email and See the Ten →

Uncapped Growth Versus Defensive Value

Lens	Lilly	Pfizer
Core Bet	Incretin dominance plus retatrutide BLA in Q1 2027	$7B Metsera obesity entry, oncology depth
2027 EPS Estimate	$47.34 avg, 27 analysts	$2.8970 avg, 25 analysts
Forward P/E	24x	9x
Dividend Yield	0.56%	6.22%
Key Vulnerability	US realized prices down ~9%, capacity limits	~$1.5B LOE headwind, obesity late

Lilly is compounding off scarcity. Pfizer is engineering a floor with yield, biosimilars, and pipeline reinvestment. Both are legitimate strategies. They just answer different questions.

2027 Catalysts Worth Marking on the Calendar

For Lilly, the swing factor is retatrutide’s BLA filing in Q1 2027 across obesity, sleep apnea, and knee osteoarthritis pain. Analyst momentum reflects it: 19 upward EPS revisions versus 4 downward in the past 30 days for FY2027. I will watch whether new Indiana manufacturing capacity closes the persistent supply gap.

For Pfizer, the tests are Metsera’s 10 pivotal starts in 2026, the Vyndamax exclusivity extended to June 2031, and Most-Favored-Nation pricing outcomes. You should also track whether oncology can keep offsetting primary-care softness.

Why I Would Park 2027 Capital in Lilly, With One Caveat

Personally, I lean Lilly for 2027. The incretin franchise is running ~$14.87B in a single quarter, retatrutide is queued, and analysts have marched EPS estimates higher. Shares are up 56.02% over the past year, so you are not buying it cheap. If you want a 6.22% yield and a lower entry multiple while a turnaround plays out, Pfizer fits. For anyone building a 2027 growth allocation, Lilly is the better place to park pharmaceutical capital, provided you can stomach the premium.

Got $1,000? Before You Buy LLY, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And LLY wasn’t one of them.

They combed the entire market. It’s not 10 ideas, not 10 stocks everyone is talking about, it’s what their research points to as the 10 best stocks to buy right now, and it’s free. Read more here and see which stocks made the list –>>

Contact editorial@247wallst.com for any questions or corrections.

What's Hot